Evidence map›Paper›PMID 39730158›Full record

ArticleAJNR. American journal of neuroradiology2025

Predicting Post-Operative Side Effects in VIM MRgFUS Based on THalamus Optimized Multi Atlas Segmentation (THOMAS) on White-Matter-Nulled MRI: A Retrospective Study.

Sonoko Oshima, Asher Kim, Xiaonan R Sun, Ziad Rifi, Katy A Cross, Katherine A Fu, Noriko Salamon, Benjamin M Ellingson, Ausaf A Bari, Jingwen Yao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in AJNR. American journal of neuroradiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sonoko OshimaFrom the UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers (S.O., A.K., B.M.E., J.Y.), University of California, Los Angeles, Los Angeles, California.
Asher KimFrom the UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers (S.O., A.K., B.M.E., J.Y.), University of California, Los Angeles, Los Angeles, California.ORCID 0009-0008-5471-5462
Xiaonan R SunDepartment of Neurosurgery (X.R.S., Z.R., B.M.E., A.A.B.), David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.
Ziad RifiDepartment of Neurosurgery (X.R.S., Z.R., B.M.E., A.A.B.), David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.ORCID 0000-0003-3545-796X
Katy A CrossDepartment of Neurology (K.A.C., K.A.F.), David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.
Katherine A FuDepartment of Neurology (K.A.C., K.A.F.), David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.ORCID 0000-0003-2043-2997
Noriko SalamonDepartment of Radiological Sciences (S.O., N.S., B.M.E., J.Y.), David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.ORCID 0000-0002-3520-9467
Benjamin M EllingsonFrom the UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers (S.O., A.K., B.M.E., J.Y.), University of California, Los Angeles, Los Angeles, California.ORCID 0000-0002-2764-6640
Ausaf A BariDepartment of Neurosurgery (X.R.S., Z.R., B.M.E., A.A.B.), David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.
Jingwen YaoFrom the UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers (S.O., A.K., B.M.E., J.Y.), University of California, Los Angeles, Los Angeles, California jingwenyao@mednet.ucla.edu.ORCID 0000-0002-8828-1841

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposePrecise and individualized targeting of the ventral intermediate thalamic nucleus for the MR-guided focused ultrasound is crucial for enhancing treatment efficacy and avoiding undesirable side effects. In this study, we tested the hypothesis that the spatial relationships between Thalamus Optimized Multi Atlas Segmentation derived segmentations and the post-focused ultrasound lesion can predict post-operative side effects in patients treated with MR-guided focused ultrasound. MATERIALS AND

methodsWe retrospectively analyzed 30 patients (essential tremor, n = 26; tremor-dominant Parkinson's disease, n = 4) who underwent unilateral ventral intermediate thalamic nucleus focused ultrasound treatment. We created ROIs of coordinate-based indirect treatment target, focused ultrasound-induced lesion, and thalamus and ventral intermediate thalamic nucleus segmentations. We extracted imaging features including 1) focused ultrasound-induced lesion volumes, 2) overlap between lesions and thalamus and ventral intermediate thalamic nucleus segmentations, 3) distance between lesions and ventral intermediate thalamic nucleus segmentation and 4) distance between lesions and the indirect standard target. These imaging features were compared between patients with and without post-operative gait/balance side effects using Wilcoxon rank-sum test. Multivariate prediction models of side effects based on the imaging features were evaluated using the receiver operating characteristic analyses.

resultsPatients with self-reported gait/balance side effects had a significantly larger extent of focused ultrasound-induced edema, a smaller fraction of the lesion within the ventral intermediate thalamic nucleus segmentation, a larger fraction of the off-target lesion outside the thalamus segmentation, a more inferior centroid of the lesion from the ventral intermediate thalamic nucleus segmentation, and a larger distance between the centroid of the lesion and ventral intermediate thalamic nucleus segmentation (

conclusionsThalamus Optimized Multi Atlas Segmentation-based patient-specific segmentation of the ventral intermediate thalamic nucleus can predict post-operative side effects, which has implications for aiding the direct targeting of MR-guided focused ultrasound and reducing side effects.

Indexed as

Essential TremorHigh-Intensity Focused Ultrasound AblationMagnetic Resonance ImagingParkinson DiseasePostoperative ComplicationsVentral Thalamic NucleiWhite MatterAgedFemaleHumansMaleMiddle AgedReproducibility of ResultsRetrospective StudiesSensitivity and SpecificityThalamus

Identifiers

PMID39730158
PMCPMC11878955

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.